Mucinex® for Treatment of Filamentary Keratitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02859246|
Recruitment Status : Completed
First Posted : August 9, 2016
Results First Posted : February 19, 2020
Last Update Posted : February 19, 2020
|Condition or disease||Intervention/treatment||Phase|
|Filamentary Keratitis||Drug: Mucinex®||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mucinex® for Treatment of Filamentary Keratitis|
|Actual Study Start Date :||September 2016|
|Actual Primary Completion Date :||July 2018|
|Actual Study Completion Date :||July 2018|
600 mg of Mucinex 2 times a day.
Other Name: Guaifenesin
- Change in Number of Corneal Filaments [ Time Frame: baseline (day 1) and week 4 ]Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.
- Change in OSDI Score [ Time Frame: baseline (day 1) and week 4 ]
Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.
Total score ranges from 0-100. Lower OSDI scores means subjects are experiencing low ocular discomfort. High OSDI scores means subjects are experiencing high ocular discomfort.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02859246
|United States, Massachusetts|
|Massachusetts Eye and Ear Infirmary|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Reza Dana, M.D,MPH,M.Sc||Massachusetts Eye and Ear Infirmary|